Figitumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Figitumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1 receptor
Legal status
Legal status
  • Experimental
Identifiers
CAS Number 943453-46-1 N
ATC code none
ChemSpider none
UNII VE267FC2UB YesY
KEGG D09345 YesY
Chemical data
Formula C6462H9948N1736O2020S54
Molar mass 146.0 kg/mol
 NYesY (what is this?)  (verify)

Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]

This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]

Anti-cancer mechanism[edit]

See Insulin-like growth factor 1 receptor role in cancer.

Clinical trials[edit]

The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]

It was to have been included in the I-SPY2 breast cancer trial.[8]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
  2. ^ Haluska, P; Worden, F; Olmos, D; Yin, D; Schteingart, D; Batzel, GN; Paccagnella, ML; De Bono, JS; et al. (2009). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer chemotherapy and pharmacology. 65 (4): 765–773. doi:10.1007/s00280-009-1083-9. PMC 2875253free to read. PMID 19649631. 
  3. ^ Gualberto, A; Karp, DD (2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer. 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947. 
  4. ^ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014. 
  5. ^ Krauskopf, Lewis (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters. 
  6. ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
  8. ^ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.